What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable”In the company’s words, NCT06277804 on ClinicalTrials.gov
- Tested for
- Adult Solid Tumor
- Main trialPhase 1
- “This was a multicenter, open PHASE I study of LTC004 in Combination With Cyclophosphamide and Fludarabine in Patients With Advanced/Metastatic Malignancies Tumor, the study design consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib expansion). The objective of this study was to evaluate combination safety, tolerability, pharmacokinetic,pharmacodynamics characteristics, and initial efficacy in advanced malignant tumors.”In the company’s words, NCT06277804 on ClinicalTrials.gov
Other drugs for Adult Solid Tumor
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up1
- 1 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 1 Jul 2027 | A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor | |
| Phase 1/2Unknown | 23 Aug 2025 | Phase II Clinical Study of LTC004 in Patients With mCRC | |
| Phase 1/2Unknown | 28 Dec 2025 | Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | |
| Phase 1Unknown | Dec 2024 | Study of LTC004 in Subjects With Advanced Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026